X @Bloomberg

AstraZeneca got a rare sell rating on Thursday as Deutsche Bank analysts downgraded the British drugmaker, taking a more skeptical view on the company’s drug pipeline, in particular for breast cancer treatments https://t.co/ursBCWKI2p ...